From In Vivo Predictive Dissolution to Virtual Bioequivalence: A GastroPlus

Hao Ruan, Xiaoting Geng, Zijing Situ, Qian Shen, Tianjian Ye, Xin Chen, Weike Su

Abstract read

In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

A nonhydrolyzable candesartan cilexetil analog reveals synergistic activation as a tractable mechanism for TMEM175 modulation.American journal of physiology. Cell physiology · 2026
Article
Guiding a Diclofenac Sodium Dual-Release Sustained Formulation Development Through In Vitro-In Vivo Relationship Based on Physiologically Based Pharmacokinetics.Pharmaceutics · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hao RuanCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0002-5186-4402

Xiaoting GengZhejiang Key Laboratory of Biopharmaceutical Contact Materials, NMPA Key Laboratory for Core Technology of Generic Drug Evaluation, Zhejiang Institute for Food and Drug Control, Hangzhou 310052, China.

Zijing SituSchool of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

Qian ShenZhejiang Key Laboratory of Biopharmaceutical Contact Materials, NMPA Key Laboratory for Core Technology of Generic Drug Evaluation, Zhejiang Institute for Food and Drug Control, Hangzhou 310052, China.

Tianjian YeZhejiang Yongning Pharmaceutical Co., Ltd., Taizhou 318020, China.

Xin ChenZhejiang Yongning Pharmaceutical Co., Ltd., Taizhou 318020, China.

Weike SuCollege of Pharmaceutical Sciences, Zhejiang University of Technology, Hangzhou 310014, China.ORCID 0000-0003-2544-1948

Funding

Science and Technology Project of Zhejiang Medical Products Administration 2023018Zhejiang Basic Public Welfare Research Program LGC22H300003

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

candesartan cilexetilflow-through cellGastroPlus®in vivo predictive dissolutionvirtual bioequivalence

Identifiers

PMID40283997

DOI10.3390/ph18040562

PMCPMC12030460

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.